BlackRock Amends Exelixis Stake, Files 17th SC 13G/A
Ticker: EXEL · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 939767
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**BlackRock just updated its Exelixis stake, watch for market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in their ownership of Exelixis Inc. common stock as of December 31, 2023. This amendment, the 17th for this holding, updates their previous disclosures. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their sentiment about Exelixis's future prospects, potentially influencing other investors and the stock price.
Why It Matters
This filing shows BlackRock's updated position in Exelixis, providing transparency on a significant institutional investor's stake, which can influence market perception and trading activity.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of institutional ownership and does not inherently present a high risk to investors.
Analyst Insight
An investor should note BlackRock's continued presence as a major shareholder in Exelixis, but this filing alone doesn't provide enough detail on the magnitude of the change to warrant immediate action. Further investigation into BlackRock's specific share count changes would be prudent.
Key Numbers
- 17 — Amendment Number (This is the 17th amendment to BlackRock's Schedule 13G filing for Exelixis, indicating a history of reporting changes.)
- 30161Q104 — CUSIP Number (This unique identifier confirms the specific class of securities (Common Stock) of Exelixis Inc. being reported.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- EXELIXIS, INC. (company) — the subject company whose shares are being reported
- January 24, 2024 (date) — the filing date of the SC 13G/A
- December 31, 2023 (date) — the date of the event requiring the filing
- 17 (number) — the amendment number for this Schedule 13G filing
Forward-Looking Statements
- BlackRock will continue to be a significant institutional holder of Exelixis stock. (BlackRock Inc.) — high confidence, target: December 31, 2024
- The market will interpret BlackRock's continued reporting as a sign of ongoing interest in Exelixis. (EXELIXIS, INC.) — medium confidence, target: March 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17)' sections.
Who is the reporting entity in this filing?
The reporting entity is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company of this filing?
The subject company is EXELIXIS, INC., as stated under the 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC.' section.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated in the filing.
How many amendments have been filed for this particular Schedule 13G by BlackRock regarding Exelixis?
This is the 17th amendment, as indicated by '(Amendment No: 17)' on the Schedule 13G form.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding EXELIXIS, INC. (EXEL).